Mirae Asset Global Investments Co. Ltd. Buys 30,627 Shares of DexCom, Inc. (NASDAQ:DXCM)

Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 20.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 178,538 shares of the medical device company's stock after purchasing an additional 30,627 shares during the period. Mirae Asset Global Investments Co. Ltd.'s holdings in DexCom were worth $12,107,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Geode Capital Management LLC raised its position in DexCom by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 9,993,698 shares of the medical device company's stock worth $775,256,000 after acquiring an additional 56,094 shares during the period. Norges Bank purchased a new position in DexCom in the fourth quarter valued at approximately $385,367,000. Northern Trust Corp lifted its stake in DexCom by 22.2% in the fourth quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company's stock valued at $322,454,000 after purchasing an additional 753,857 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in DexCom by 3.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,825,206 shares of the medical device company's stock valued at $219,716,000 after purchasing an additional 91,051 shares during the period. Finally, Artisan Partners Limited Partnership increased its position in DexCom by 12.2% in the fourth quarter. Artisan Partners Limited Partnership now owns 1,853,565 shares of the medical device company's stock worth $144,152,000 after buying an additional 201,181 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

Insider Transactions at DexCom

In other DexCom news, Director Mark G. Foletta sold 2,750 shares of the company's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $83.13, for a total value of $228,607.50. Following the completion of the sale, the director owned 56,621 shares of the company's stock, valued at $4,706,903.73. This represents a 4.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael Jon Brown sold 500 shares of the stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $82.80, for a total transaction of $41,400.00. Following the transaction, the executive vice president owned 95,102 shares in the company, valued at $7,874,445.60. The trade was a 0.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 27,190 shares of company stock worth $2,281,732. 0.32% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on DXCM shares. Truist Financial assumed coverage on DexCom in a research report on Monday, June 16th. They set a "buy" rating and a $102.00 price target on the stock. Cfra Research raised shares of DexCom to a "hold" rating in a report on Friday, March 21st. Citigroup reiterated a "buy" rating and issued a $102.00 target price (up previously from $82.00) on shares of DexCom in a research note on Thursday, May 22nd. Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Finally, Mizuho initiated coverage on shares of DexCom in a report on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price objective for the company. Five research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, DexCom currently has an average rating of "Moderate Buy" and a consensus price target of $98.50.

DexCom Price Performance

Shares of DXCM stock traded down $3.71 during trading on Tuesday, hitting $83.58. The company had a trading volume of 5,587,879 shares, compared to its average volume of 4,394,654. The stock's 50-day moving average is $82.12 and its two-hundred day moving average is $79.66. The stock has a market capitalization of $32.77 billion, a price-to-earnings ratio of 62.37, a price-to-earnings-growth ratio of 1.86 and a beta of 1.44. The company has a quick ratio of 1.32, a current ratio of 1.50 and a debt-to-equity ratio of 0.55. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $117.19.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a return on equity of 30.05% and a net margin of 12.90%. The company had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. During the same period in the previous year, the company earned $0.32 EPS. DexCom's quarterly revenue was up 12.5% on a year-over-year basis. As a group, analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.